FDA Introduces New Term "Nonclinical Tests" Signaling a Beginning, Not an End
For the past 60 years, US law has empowered the FDA to require that clinical trial sponsors submit...
For the past 60 years, US law has empowered the FDA to require that clinical trial sponsors submit...
Based on an online seminar presentation made in collaboration with TOPRA and Veristat, this article...
RECIST (Response Evaluation Criteria in Solid Tumors) guidelines were introduced over twenty years...
Were you able to join Veristat’s live webinar- “Strategies for Solving the Challenges of an...
Each year, Veristat regulatory experts present timely, relevant topics to members of The...
Veristat developed a thorough regulatory submission strategy and...
Clinical trials involving gene therapies for the treatment of Central Nervous System (CNS)...
As we are well-rooted...
The Food and Drug Administration (FDA) has started encouraging the use of adaptive designs for...